EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

South American Gold Corp (SAGD) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of South American Gold Corp $0.00, price $0.00, upside +0.0%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US8363012001

SA South American Gold Corp logo Thin data Sep 27, 2026

South American Gold Corp

SAGD · US

Low PriorityFair Value upside is limited and quality is weak.

Generates free cash flow
Fair value $0.0001 · Fairly valued (+0.0%)
Quality 46/100
Mixed Growth (revenue 3y +38.1 %/yr in USD)
Negative equity (buybacks among others)
Mixed vs. peers (2/5)
Narrow moat 23/100
Thin data

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.0358 $0.0001 Fair Value $0.0001 Jul 2017 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $0.0001 – $0.0358 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow South American Gold in your weekly email

Every Wednesday you see whether South American Gold is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

South American Gold Corp. is focused on becoming the premiere provider of value added products and services for the cultivation and processing of cannabis for the South American medical and recreational markets with an initial focus on the Uruguayan market.

Stock analysis

South American Gold Corp (SAGD) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $0.0001 per share, and 0 of the 4 models we run sit above the $0.0001 price.

Bear case: the DCF Models group reads lowest at $0.0001, and 4 of the 4 models stay below the price. Evidence for this calculation is low.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

South American Gold Corp reported revenue of $20.0K in FY2018 versus $0 in FY2014. Reported net income was −$119K in FY2018.

Key figures

Market cap $66.8K · Return on assets (EBIT) −620% · Free cash flow $484K · Net debt $344K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 0%, SAGD screens cheaper than that median.

Fair Value models

Bear $0.0001 Fair Value $0.0001 Bull $0.0001
Price $0.0001 · Upside +0.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $0.0001 $0.0001 $0.0002 70
Growth DCF $0.0001 $0.0001 $0.0002 68
5Y EBITDA Exit n/a n/a $0.0001 67
All 6 models by family
DCF Models
FCF DCF $0.0001 $0.0001 $0.0002 70
5Y Revenue Exit n/a n/a $0.0001 65
5Y EBITDA Exit n/a n/a $0.0001 67
10Y Revenue Exit $0.0001 $0.0001 $0.0001 64
10Y EBITDA Exit $0.0001 $0.0001 $0.0001 65
Growth DCF
Growth DCF $0.0001 $0.0001 $0.0002 68

Open the full fair value analysis →

Notify me when SAGD reaches fair value

Put SAGD on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 46/100

Of which business quality 49 · Market factors (momentum, volatility) 50

Profitability 39
Margins and returns on capital today
Quality Growth 70
Are margins and returns improving?
Cashflow 100
Earnings quality: real cash, not paper profit
Fin. Strength 8
Balance sheet, leverage, solvency risk
Investment 50
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 50
Price trend over the last 3–12 months (market factor)
Net Issuance 28
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 52/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+144.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−983.0% (2015) → −47.7% (2018)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2018 is a loss year, no rate is defined from a loss
not computed

Watch SAGD, get fair value alerts →

Compare South American Gold Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 600 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 46 · Below median
Fair Value upside +0.0% · Above median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Operating margin (TTM) 0.0% · Below median
Growth and dividend
Revenue growth 0.0% · Below median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/FCF 0.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)33 · sector 17
FUTURE (revenue growth)0 · sector 24
PAST (return on equity)0 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 31

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $17.86 $11.35 −36%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $69.69 $110.50 +59%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "South American Gold Corp Fair Value". https://www.fairvalue-calculator.com/stock/SAGD

Frequently asked questions

Is South American Gold Corp (SAGD) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001, about +0% upside (fairly valued).
What is the fair value of SAGD?
Our model-based fair value for South American Gold Corp is $0.0001 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.0001.
What is the quality score of SAGD?
South American Gold Corp has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for South American Gold Corp (SAGD)?
Our model-based price target is the fair value of $0.0001 (as of Sep 27, 2026) from 6 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the South American Gold Corp stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus a price of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of South American Gold Corp (SAGD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For South American Gold Corp it is $0.0001 per share (as of Sep 27, 2026), against a price of $0.0001. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is South American Gold Corp stock overvalued or undervalued in 2026?
As of Sep 27, 2026, SAGD trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SAGD?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For South American Gold Corp the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is South American Gold Corp worth?
The market values South American Gold Corp at about $66.8K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of South American Gold Corp (SAGD)?
Balance-sheet figures for South American Gold Corp (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
Which stocks are comparable to South American Gold Corp?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is South American Gold Corp stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 46/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SAGD calculated?
We run South American Gold Corp through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. South American Gold Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of South American Gold Corp (SAGD)?
The closing price on Oct 2, 2026 was $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with South American Gold Corp right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of South American Gold Corp

How large is the market capitalisation of South American Gold Corp (SAGD)?
The market capitalisation of South American Gold Corp is $66.8K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the EBIT return on assets of South American Gold Corp (SAGD)?
On an EBIT basis the return on assets of South American Gold Corp is −620% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does South American Gold Corp (SAGD) generate?
The free cash flow of South American Gold Corp is $484K (fiscal year 2018). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does South American Gold Corp (SAGD) carry?
The net debt of South American Gold Corp is $344K (fiscal year 2018, ≈ 0.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch South American Gold Corp in the live analysis

One click puts South American Gold Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.